ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM
Abstract Number: 1770
Assessing S100A4 and Myofibroblast Phenotypes in the Pathogenesis of Cardiac and Cutaneous Neonatal Lupus
Pediatric Rheumatology – Basic Science Poster
10:30AM-12:30PM
Abstract Number: 1875
Assessing the PULSAR (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry for Environmental Determinants of Heath Research
Epidemiology & Public Health Poster III
10:30AM-12:30PM
Abstract Number: 2281
Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab
RA – Treatment Poster III
10:30AM-12:30PM
Abstract Number: 2249
Assessment of Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A National Multicenter Observational Study from the MAJIK-SFR Registry
RA – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2361
Assessment of Laboratory Parameter Changes in a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Highly Selective TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis
SpA Including PsA – Treatment Poster III
10:30AM-12:30PM
Abstract Number: 2331
Assessment of the Likelihood of Joint Inflammation Recurrence in Previously Affected Joints During Psoriatic Arthritis Disease Course
SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 1895
Association Between a History of Mental Illness and the Risk of Systemic Autoimmune Rheumatic Diseases: A Nationwide, Population-based Case-control Study
Epidemiology & Public Health Poster III
10:30AM-12:30PM
Abstract Number: 2218
Association Between Frailty and Peri-Operative Inpatient Adverse Outcomes Among Patients with and Without Rheumatoid Arthritis
RA – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2221
Association Between Serum Uric Acid/Serum Creatinine Index and Carotid Plaque in Patients with Rheumatoid Arthritis
RA – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 1998
Association Between Small Interfering RNA Therapy and Autoimmune Diseases: U.S. Prospective Cohort Study
Immunological Complications of Medical Therapy Poster
10:30AM-12:30PM
Abstract Number: 2110
Association Between Symptomatic Knee Osteoarthritis and Blood Glucose Control in Persons with Type 2 Diabetes
Osteoarthritis – Clinical Poster II
10:30AM-12:30PM
Abstract Number: 2058
Association of Anti-Synthetase Antibody Subtypes with Radiographic Progression of Interstitial Lung Disease in Anti-Synthetase Syndrome: An Analysis of the CLASS Project Database
Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III
10:30AM-12:30PM
Abstract Number: 2219
Association of Chondrocalcinosis with Disease Activity and Drug Response in Rheumatoid Arthritis: Baseline Characteristics of the Swiss Rheumatoid Arthritis Outcomes Cohort
RA – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 2295
Association of Early Markers in Patients with Sjögren’s Syndrome in a Diverse Academic Cohort
Sjögren's Syndrome – Basic & Clinical Science Poster II
10:30AM-12:30PM
Abstract Number: 2248
Association of Integrative Health Practices with Health-Related Quality of Life in Women with Rheumatoid Arthritis
RA – Diagnosis, Manifestations, & Outcomes Poster III
  • «Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 61
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology